logo-loader
viewIXICO PLC

Ixico wins second imaging services contract with Vaccinex

On an existing project with Vaccinex in Huntington's disease, positive imaging results obtained in an interim analysis indicated the drug's potential in additional therapeutic areas

IXICO PLC -
Ixico's technology helps with the analysis of MRI scans

Ixico PLC (LON:IXI) has won an extended contract with Vaccinex Inc (NASDAQ:VCNX), to provide services on a trial of a potential treatment for Alzheimer’s disease.

The AIM-listed data analytics company has been awarded a contract to provide imaging services for Vaccinex’s planned phase Ib/IIa trial for its pepinemab as an Alzheimer’s treatment.

READ: Ixico to present three posters at California Alzheimer's conference

Ixico already is supporting the US immunotherapy company’s SIGNAL trial by providing imaging services Phase II study of pepinemab as a treatment for Huntington's disease.

The company’s digital platform and artificial intelligence (AI) software manages and helps interpret images from magnetic resonance imaging (MRI) and other scanners.

“This AD trial, called SIGNAL-AD, is part of a new wave of investment in treatments for neurodegeneration by the global biopharmaceutical industry, with additional assets being brought through the pipeline thanks to the insights unlocked in earlier research programmes,” said Giulio Cerroni, chief executive of Ixico.

In the existing project with Vaccinex in Huntington's disease, Cerroni said the positive imaging results obtained in an interim cohort analysis indicated its potential in additional therapeutic areas.

After the previous contract was initiated in 2017, he said the new award “is a great testament to the achievements of our two organisations working diligently together since then”.

Last month, Ixico joined the Alzheimer's Disease Neuroimaging Initiative (ADNI), with two of the company's scientists joining the private partner scientific board of ADNI, which is a longitudinal multicentre study looking to develop clinical, imaging, genetic and biochemical biomarkers for the early detection and tracking of Alzheimer's disease.

Quick facts: IXICO PLC

Price: 70 GBX

AIM:IXI
Market: AIM
Market Cap: £32.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

IXICO sees strong topline growth in interim results

IXICO Plc's (LON:IXI) Giulio Cerroni tells Proactive that the company is seeing topline growth of 30% in a strong set of interim results. Cerroni says the company is also seeing improvements in its gross margins and cash position. He adds that the company recently raised £5.5mln...

on 23/5/18

2 min read